ClinicalTrials.gg
Not yet recruitingNCT06245967Updated Feb 7, 2024

Frequency Specific Microcurrent Therapy for Mild Traumatic Brain Injury

An interventional study of Frequency specific microcurrent therapy and Sham Frequency specific microcurrent therapy in Trauma, Head, Headaches Posttraumatic and Dizziness, sponsored by China Medical University Hospital. Not yet recruiting. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-07.

Primary conditionBrain ConcussionRegistry: Craniocerebral TraumaReclassifiedWhy we changed it
Registry
Craniocerebral Trauma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Brain Concussion
Why
  1. The study's listed conditions name Brain Concussion, a narrower term within Craniocerebral Trauma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by China Medical University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

Patients with mild traumatic brain injury (mTBI) may experience spontaneous recovery within 7-10 days, but some continue to exhibit symptoms such as headache, dizziness, vertigo, poor concentration, and cognitive dysfunction. Effective treatments for these symptoms are currently lacking. Frequency Specific Microcurrent(FSM) has received approval from the U.S. FDA for use in neuroinflammatory conditions. Our study aims to evaluate the efficacy of FSM by using FSM device ,IS02LCDs Stimulator (Ru Yi Health ltd. Co,Taiwan R.O.C), on symptom improvement in 52 patients with mild TBI

Read the detailed description

This study is a single center double-blind randomized sham-controlled trail.We aims to recruit 52 mild traumatic brain injury participants with symptoms for more than 10 days.Clinical assessments include Post-Concussion Symptom Scale (PCSS) scores, and the amount of medication used for symptom management. These 52 participants will be 1:1 randomly allocated into two groups (1) sham FSM with symptom management medication and (2) True FSM with symptom management medication. The treatment period will last two weeks, with a total of six therapy sessions. Following treatment, a four-week observation period will be conducted. The primary outcome measurement will be changes in the Post-Concussion Symptom Scale (PCSS) scores, recorded at baseline, after the third treatment session, at the end of treatment, and at the end of the observation period. Secondary outcome measures will include the amount of medication used for symptom management. The safety evaluated index is the adverse event rate for two groups. These assessments aim to evaluate the therapeutic benefits of FSM for mild traumatic brain injury.

02

Conditions studied

  • Trauma, Head
  • Headaches Posttraumatic
  • Dizziness
  • Brain Concussion
  • Frequency Specific Microcurrent Therapy

Keywords

  • Frequency specific microcurrent therapy
  • Concussion
  • Traumatic brain injury
03

In context

Brain Concussion Reclassified

637 studies on the registry are indexed under Brain Concussion; 163 are open to participants now.

This study's planned enrollment of 52 is below the median of 63 across 446 interventional studies indexed under Brain Concussion.

Browse Brain Concussion studies →

Lead sponsor

China Medical University Hospital is the lead sponsor of 479 studies on the registry; 115 are open to participants now.

Compared within Brain Concussion, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Craniocerebral Trauma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 20 and 65, inclusive, for both males and females.
  2. History of traumatic brain injury with a loss of consciousness lasting less than 30 minutes, initial Glasgow Coma Scale (GCS) score ranging from 13 to 15.
  3. Presence of persistent post-concussion symptoms starting from the day of injury and lasting for more than ten days.
  4. Complete consciousness or decision-making capacity at the time of enrollment.
  5. Brain imaging through CT or MRI indicating the absence of significant midline shift, no evident damage to the brainstem (excluding the pyramidal tract), or thalamus. Each brain lobe lesion should not exceed 30% of the respective cerebral hemisphere.

Exclusion criteria

Exclusion Criteria:

  1. Individuals below 20 years or above 65 years of age, regardless of gender.
  2. History of traumatic brain injury with a loss of consciousness exceeding 30 minutes, initial Glasgow Coma Scale (GCS) score less than 13.
  3. Not a first-time occurrence of traumatic brain injury.
  4. Brain imaging through CT or MRI revealing significant midline shift, evident damage to the brainstem or thalamus, with each brain lobe lesion exceeding 30% of the respective cerebral hemisphere.
  5. Presence of comorbidities such as cancer, depression.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Experimental

    True FSM (Concussion protocol) with symptom management medication

    Device: Frequency specific microcurrent therapy

  • Sham comparator
    Sham-control

    Sham FSM (no protocol) with symptom management medication

    Device: Sham Frequency specific microcurrent therapy

Interventions

  • DeviceFrequency specific microcurrent therapy

    Concussion protocol

  • DeviceSham Frequency specific microcurrent therapy

    Shan concussion protocol

06

What researchers measure

Primary outcomes

  1. Post-Concussion Symptom Scale (PCSS) scores

    The Post-Concussion Symptom Scale (PCSS) is used to assess the number and intensity of symptoms after a concussion/mild traumatic brain injury.

    Time frame: 1.5 month

Secondary outcomes

  1. the amount of medication used for symptom management

    the amount of medication used for symptom management

    Time frame: 1.5 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06245967
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
Feb 15, 2024 (estimated)
Primary completion
Feb 28, 2026 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Feb 7, 2024

Study contacts

I HAN Hsiao
Contact
coolfishing2002@gmail.com
+886933668642
CHEPIN CHANG
Contact
freedyrae@gmail.com
+886934073950
I HAN Hsiao
principal investigator · China Medical University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion